Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Healthcare
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.


TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc > Volume
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9675)
•••
Comment by Larrymartin77on May 28, 2022 5:15pm
142 Views
Post# 34714777

RE:Volume

RE:Volume
Launch64 wrote: 7.2 million
Starting to come from out of the shadows!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities